Axim Biotechnologies Inc (AXIM)

[OTCRIDER]

News & Analysis


Mar 5, 2015 Photo Release -- AXIM Biotech Unveils World's First Hemp Cannabigerol (CBG) Oral Care & Cosmetic Products GlobeNewswire
Feb 19, 2015 AXIM Biotechnologies, Inc. Announces Cosmetics Division GlobeNewswire
Feb 12, 2015 AXIM Biotechnologies, Inc. Announces Hemp-Based Oral Care Division GlobeNewswire
http://www.otcmarkets.com/stock/AXIM/news


AXIM Security Details
Share Structure
Market Value1 ...............$34,650,000 a/o Mar 13, 2015
Shares Outstanding ...............33,000,000 a/o Aug 13, 2013
Float.............................. Not Available
Authorized Shares............... 195,000,000 a/o Sep 30, 2012
Par Value 0.0001

Business Description
We were incorporated in the State of Nevada on November 18, 2010, as AXIM International, Inc. On July 24, 2014, we changed our name to AXIM Biotechnologies, Inc. to better reflect our business operations. Our principal executive office is located at 18 East 50th Street, 5th Floor, New York, NY 10022.
In early 2014, we discontinued our organic waste marketable by-product business to focus on our anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids based products as well as focusing on research, development and production of pharmaceutical, nutriceutical and cosmetic products as well as procurement of genetically and nano-controlled active ingredients.
Going forward, the Companyâ??s board of directors intends to broaden the current operations of the Company to include pharmaceutical products, manufacturing facilities, genetically controlled botanical products, extraction and purification of biomaterials technologies. These activities are anticipated to include the following:
-Supporting a clinical trial for a novel (patent pending) delivery form of cannabinoids for treatment of pain and spasticity in patients with multiple sclerosis.
-Conducting research trials of a novel delivery mechanism (patent pending) for treatment of patients with ADHD.
-Development of novel pharmaceutical and nutriceutical formulations including smoking cessation, cannabinoid based preparation.
-Development of 95% pure, freeze-dried cannabinoids products, high-energy-output hemp coal â??CannaCoal,â? sustainable biofuel compositions derived from industrial hemp by-products.
-A land purchase in the city of Almere, in the province of Flevoland, The Netherlands for building of a state of the art extraction facility as well as a factory for pharmaceutical and nutriceutical preparations.
-Importation from Italy, Spain and other reputable producers of pharmaceutical grade hemp oil to Europe and North America.

Contact Info
18 E 50th St
5th Floor
New York, NY 10022

http://aximbiotech.com/